Premium
Do formulation switches exacerbate existing medical illness? Results of an open‐label transition to orally disintegrating risperidone tablets
Author(s) -
Chue Pierre,
Prinzo Rosanna S.,
Binder Carin E.
Publication year - 2007
Publication title -
human psychopharmacology: clinical and experimental
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.461
H-Index - 78
eISSN - 1099-1077
pISSN - 0885-6222
DOI - 10.1002/hup.852
Subject(s) - risperidone , medicine , clinical global impression , adverse effect , schizophrenia (object oriented programming) , side effect (computer science) , psychiatry , alternative medicine , pathology , computer science , programming language , placebo
Background Orally disintegrating risperidone tablets (Risperdal* M‐TABs*) present an alternative method of drug delivery that may benefit physicians struggling to treat non‐compliant patients, since it begins to dissolve within 5 s, preventing tablet cheeking or spitting. Objectives To evaluate safety and maintenance of effect in symptomatically stable patients transitioned from compressed risperidone tablets to orally disintegrating risperidone tablets. Methods This open‐label, multi‐centre study enrolled 82 adults from four diagnostic groups (major depressive disorder (MDD), n = 25; bipolar disorder (BP), n = 21; dementia (DE), n = 20; schizophrenia (SZ), n = 16). Patients were switched from their previous dosage of compressed tablets (0.5, 1.0, 2.0, 3.0, or 4.0 mg/day) to an equivalent dosage of orally disintegrating risperidone and followed for 4 weeks. The primary effectiveness parameter evaluated was the Clinical Global Impression—Severity (CGI‐S) scale. Results Most patients (24/25 MDD; 20/21 BP; 17/18 DE; 14/15 SZ) improved by 1 point on CGI‐S from baseline or experienced no change at endpoint. Adverse events (AEs) occurring in any group at a ≥10% incidence included headache (19%) and pharyngolaryngeal pain (10%), reported in the BP group only. Conclusions Patients stabilized on compressed risperidone tablets transitioned to the equivalent dose of orally disintegrating risperidone tablets with continued maintenance of effect, no decompensation and with minimal side effects. Copyright © 2007 John Wiley & Sons, Ltd.